GNRH1 and lung carcinoma: The MSN-drug-siRNA conjugate was targeted to lung cancer cells by conjugating a luteinizing hormone-releasing hormone (LHRH) peptide, whose receptor is overexpressed in many cancer types including lung cancer (46) The MSN-drug-siRNA conjugate was fluorescently labelled, and fluorescence intensity was measured in different organs three hours after the drug was administered to lung cancer mouse models either by inhalation or intravenously.